Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRESOR: Switching from Olanzapine to Risperidone LAI
NCT00216632Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2005
- Primary completion
- Jul 2007
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of risperidone in schizophrenia and schizoaffective disorder (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Positive and Negative Syndrome Scale at 6 months. Started Mar 2005; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00216632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216632.